Table 4.
Notable clinical studies of anti-inflammatory therapies in heart failure patients.
| Trial | Intervention | Design | Outcome |
|---|---|---|---|
| RENEWAL | Etanercept in heart failure patients (NYHA II-IV) | Two double-blinded RCTs with placebo as control; n = 2048 | No significant clinical benefits of etanercept over placebo |
| ATTACH | Infliximab in heart failure patients (NYHA III-IV) | Double-blinded RCT with placebo as control; n = 150 | No significant clinical benefits. High dose infliximab increased mortality |
| Prednisone in Idiopathic Dilated Cardiomyotpathy | Prednisone in patients with idiopathic dilated cardiomyopathy | Single-blinded RCT with placebo as control; n = 102 | No significant clinical benefits with prednisone over placebo |
| CORONA | Rosuvastatin in heart failure patients (NYHA II-IV) | Double-blinded RCT with placebo as control; n = 5011 | Reduction in hospitalization rates if patient has multiple admissions or CRP >2 |
| GISSI-HF | Rosuvastatin in heart failure patients (NYHA II-IV) | Double-blinded RCT with placebo as control; n = 4574 | No significant clinical benefits with rosuvastatin over placebo |
| METIS | Methotrexate plus folic acid in ischaemic heart failure patients | Double-blinded RCT with placebo and folic acid as control; n = 50 | No significant clinical benefits with methotrexate over placebo |